spondyloarthropathy: A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
77 |
4. Check minimum number of eventsNone |
77 |
5. Include endpointsNone |
77 |
6. Filter based on genotype QC (FinnGen only) |
76 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M46
- Name in latin
- Aliae spondylopathiae infectiosae
Similar endpoints
↥List of similar endpoints to
Other infective spondylopathies
based on the number of shared cases.
Similar with more cases:
- Autoimmune diseases related-to ILD
- Spondylopathies
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 542 | 218 | 318 |
| Only index persons | 472 | 194 | 278 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 62.03 | 62.76 | 61.63 |
| Only index persons | 61.15 | 61.14 | 61.16 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 76 | 36 | 40 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | 62.15 | 62.60 | 61.74 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 77
- Matched controls
- 770
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M46.5
ICD-10 Finland
Other infective spondylopathies
+∞
110.7
77
*
M48.0
ICD-10 Finland
Spinal stenosis
114.0
23.2
24
*
M46.4
ICD-10 Finland
Discitis, unspecified
+∞
23.1
21
*
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
100.8
21.0
22
*
N02AX02
ATC
tramadol; systemic, rectal
9.9
20.0
59
192
M46.3
ICD-10 Finland
Infection of intervertebral disc (pyogenic)
+∞
19.6
18
*
N03AX16
ATC
[U] pregabalin
8.2
18.2
34
68
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
44.1
16.7
20
6
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
183.4
15.0
15
*
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
12.9
12
*
M54.5
ICD-10 Finland
Low back pain
5.5
12.0
33
92
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
140.1
11.8
12
*
J04AB02
ATC
rifampicin; systemic
140.1
11.8
12
*
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
+∞
11.8
11
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
7.0
11.6
21
39
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
51.4
11.3
13
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.0
10.6
23
51
R50.9
ICD-10 Finland
Fever, unspecified
5.2
9.6
25
65
J01MA12
ATC
levofloxacin; systemic
4.9
9.5
28
81
J01FF01
ATC
clindamycin; systemic
4.2
8.9
37
138
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.4
8.9
21
50
L03
ICPC
Low back symptom/complaint
4.6
8.9
28
85
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
+∞
8.5
8
*
N02AA05
ATC
oxycodone; systemic
4.2
7.7
27
88
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.8
7.6
43
194
ABC16
NOMESCO Finland
Microsurgical excision of lumbar intervertebral disc displacement
+∞
7.4
7
*
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
33.5
7.3
9
*
M54.9
ICD-10 Finland
Dorsalgia, unspecified
8.7
6.8
14
19
M45
ICD-10 Finland
Ankylosing spondylitis
75.9
6.5
7
*
C03CA01
ATC
furosemide; systemic
3.3
6.4
40
188
J01MA02
ATC
ciprofloxacin; systemic
3.2
6.0
40
193
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
13
14
10.90
7.11
1.7
1.5
—
—
—
0
0
44
213
3.49
6.78
4.6
3.1
—
—
—
0
0
16
31
6.23
6.13
1.6
1.1
—
—
—
0
0
10
10
11.27
5.72
2.0
1.0
—
—
—
0
0
23
83
3.53
5.47
2.8
1.9
—
—
—
0
0
15
41
4.30
5.22
2.2
1.5
—
—
—
0
0
54
328
3.16
5.19
17.9
9.9
4.76
4.10
e9/l
1.07
49
296
15
36
4.92
4.85
2.8
2.5
40.71
51.75
ml/min/173m2
—
7
16
50
303
2.85
4.61
17.2
13.2
1.26
1.35
inr
0.27
17
91
45
263
2.71
4.38
2.9
2.4
—
—
—
0
0
23
95
3.03
4.32
3.9
2.6
2.41
1.72
e6/l
0.22
16
59
13
32
4.67
4.14
15.5
8.3
26.29
24.87
mmol/l
0.69
13
32
17
60
3.35
4.11
3.0
1.7
—
—
—
0
0
17
60
3.35
4.11
3.1
1.8
—
—
—
0
0
32
162
2.67
4.09
4.0
3.0
0.33
0.42
e6/l
0.15
25
122
10
19
5.88
3.98
1.7
1.4
—
—
—
0
0
16
56
3.34
3.91
3.6
1.9
0.19
0.21
g/l
0.63
16
51
21
92
2.76
3.49
4.0
2.8
2.47
2.32
e6/l
0.03
14
57
7
10
7.56
3.44
1.3
1.2
—
—
—
0
0
45
287
2.37
3.34
14.2
6.4
1.20
1.22
mmol/l
0.69
40
237
8
16
5.44
3.14
1.1
1.5
—
—
—
0
0
26
140
2.29
2.76
2.6
2.2
—
—
—
0
0
9
25
3.93
2.67
1.9
2.0
—
—
—
0
0
40
261
2.11
2.61
7.1
3.8
31.89
35.23
g/l
2.44
40
243
11
38
3.20
2.54
21.4
9.2
93.62
94.54
%
0.37
11
38
37
242
2.02
2.33
1.8
1.8
90.29
89.13
pmol/l
0.05
18
112
43
300
1.98
2.23
3.2
2.4
—
—
—
0
0
16
77
2.36
2.15
4.7
4.7
1.19
1.05
mmol/l
0.50
16
71
5
10
5.26
2.10
2.6
4.2
—
—
—
0
0
9
32
3.05
2.08
4.0
1.1
9.18
10.57
g/l
—
9
27
9
33
2.95
2.01
2.0
1.1
—
—
—
0
0
13
61
2.36
1.84
6.5
2.6
—
—
—
0
0
39
278
1.82
1.77
7.7
3.5
0.00
0.00
estimate
—
8
59
10
40
2.72
1.74
5.9
2.2
0.60
0.64
%
—
10
40
10
41
2.65
1.72
23.2
8.7
1.57
1.23
%
—
10
41
10
41
2.65
1.72
23.2
8.7
0.64
0.62
%
—
10
41
10
41
2.65
1.72
6.8
2.3
1.17
1.06
%
—
10
41
39
281
1.79
1.69
7.9
3.5
0.00
0.00
estimate
—
6
49
39
281
1.79
1.69
10.2
4.7
0.00
0.00
estimate
—
8
54
5
15
3.49
1.55
1.8
1.3
—
—
—
0
0
11
54
2.21
1.41
8.9
3.6
1.21
1.23
mmol/l
0.50
11
47
5
18
2.90
1.30
1.8
2.4
—
—
—
0
0
5
19
2.74
1.23
1.2
1.3
—
—
—
0
0
14
81
1.89
1.18
1.1
1.2
0.84
23.33
u/ml
—
7
26
5
20
2.60
1.17
2.2
1.8
75.80
85.05
%
—
5
20
17
106
1.77
1.15
6.5
3.1
0.80
0.82
mmol/l
0.39
17
100
15
90
1.83
1.14
1.3
1.3
55.57
43.58
iu/ml
—
6
32
7
33
2.23
1.09
4.0
1.6
—
—
—
0
0
14
85
1.79
1.03
22.3
6.4
102.79
104.07
mmol/l
0.41
14
85
67
602
1.87
1.02
44.4
12.9
37.42
22.87
mg/l
2.23
61
465
34
262
1.53
1.01
6.1
3.4
30.94
53.98
ng/l
0.74
28
193
5
23
2.25
0.77
1.6
1.2
—
—
—
0
0
28
221
1.42
0.69
3.6
3.9
8.43
11.54
mg/mmol
0.23
16
135
20
150
1.45
0.64
9.9
3.7
0.00
0.00
estimate
—
8
53
9
61
1.54
0.56
1.1
1.4
—
—
—
0
0
59
634
0.70
0.56
5.4
5.2
2.51
2.65
mmol/l
0.67
53
566
27
220
1.35
0.54
9.6
3.7
—
—
—
0
0
11
76
1.52
0.51
1.2
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.5
—
0.87
—
0
13
67
646
1.29
0.24
42.6
15.3
139.06
139.71
mmol/l
1.36
67
622
45
420
1.17
0.23
3.0
3.8
14.60
15.13
pmol/l
0.57
38
366
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
9
80
1.14
0.16
14.2
7.1
—
—
—
0
0
60
584
1.12
0.10
33.9
13.0
79.18
76.93
ml/min/173m2
0.34
53
475
20
184
1.12
0.10
4.1
4.1
24.80
22.15
%
—
10
88
67
657
1.15
0.09
42.8
16.0
77.00
79.63
umol/l
0.39
67
657
52
519
1.01
0.00
46.2
16.1
15.02
15.24
%
0.15
52
513
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_SPONDYLOINFECTION and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_SPONDYLOINFECTION | 1.757 [1.21, 2.55] | 0.003 |
| Birth year | 0.998 [0.99, 1.01] | 0.609 |
During the follow-up period (1.1.1998 — 31.12.2019), 73 out of 189 females with M13_SPONDYLOINFECTION died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_SPONDYLOINFECTION | 1.879 [1.35, 2.62] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 102 out of 266 males with M13_SPONDYLOINFECTION died.
Mortality risk
Mortality risk for people of age
years, who have M13_SPONDYLOINFECTION.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.202% | 0.326% |
| 5 | 1.082% | 2.174% |
| 10 | 2.763% | 5.34% |
| 15 | 5.439% | 9.837% |
| 20 | 9.668% | 17.039% |
Relationships between endpoints
↥Index endpoint: M13_SPONDYLOINFECTION – Other infective spondylopathies
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data